VRC01 gp120 complex: Difference between revisions

Line 2:

==Introduction==

HIV-1 has a high level of antigenic and genetic diversity. HIV-1 has also evolved mechanisms to evade the humoral immune response. These aspects of HIV-1 have made it difficult to develop a vaccine. After several years of infection, 10 to 25% of HIV-1 infected individuals develop neutralizing antibodies. Some antibodies target the transmembrane gp41 molecules of the HIV-1 viral spike, however most target the surface protein gp120. <ref name="wu">PMID: 21835983</ref> VRC01 and VRC01-like antibodies bind to gp120 and are able to neutralize about 90% of HIV-1 isolates. Structural analysis has shown which characteristics of antibodies are essential to its binding with gp120. ~~(Kwong)~~ Discovery of the structure of these antibodies can help develop an effective HIV-1 vaccine.

HIV-1 has a high level of antigenic and genetic diversity. HIV-1 has also evolved mechanisms to evade the humoral immune response. These aspects of HIV-1 have made it difficult to develop a vaccine. After several years of infection, 10 to 25% of HIV-1 infected individuals develop neutralizing antibodies. Some antibodies target the transmembrane gp41 molecules of the HIV-1 viral spike, however most target the surface protein gp120. <ref name="wu">PMID: 21835983</ref> VRC01 and VRC01-like antibodies bind to gp120 and are able to neutralize about 90% of HIV-1 isolates. Structural analysis has shown which characteristics of antibodies are essential to its binding with gp120<ref>PMID: 22789610</ref>. Discovery of the structure of these antibodies can help develop an effective HIV-1 vaccine.

==HIV-1 Neutralization==

VRC01 gp120 complex: Difference between revisions

Navigation menu

Page actions

Page actions

Personal tools

Navigation

Search

Tools

@@ Line 2: / Line 2: @@
 ==Introduction==
-HIV-1 has a high level of antigenic and genetic diversity.  HIV-1 has also evolved mechanisms to evade the humoral immune response.  These aspects of HIV-1 have made it difficult to develop a vaccine.  After several years of infection, 10 to 25% of HIV-1 infected individuals develop neutralizing antibodies.  Some antibodies target the transmembrane gp41 molecules of the HIV-1 viral spike, however most target the surface protein gp120. <ref name="wu">PMID: 21835983</ref> VRC01 and VRC01-like antibodies bind to gp120 and are able to neutralize about 90% of HIV-1 isolates.  Structural analysis has shown which characteristics of antibodies are essential to its binding with gp120. (Kwong)  Discovery of the structure of these antibodies can help develop an effective HIV-1 vaccine.
+HIV-1 has a high level of antigenic and genetic diversity.  HIV-1 has also evolved mechanisms to evade the humoral immune response.  These aspects of HIV-1 have made it difficult to develop a vaccine.  After several years of infection, 10 to 25% of HIV-1 infected individuals develop neutralizing antibodies.  Some antibodies target the transmembrane gp41 molecules of the HIV-1 viral spike, however most target the surface protein gp120. <ref name="wu">PMID: 21835983</ref> VRC01 and VRC01-like antibodies bind to gp120 and are able to neutralize about 90% of HIV-1 isolates.  Structural analysis has shown which characteristics of antibodies are essential to its binding with gp120<ref>PMID: 22789610</ref>.  Discovery of the structure of these antibodies can help develop an effective HIV-1 vaccine.
 ==HIV-1 Neutralization==